Condition deep-dive · 7 min read

Hashimoto's thyroiditis — supplement adjuncts with actual trial evidence

Updated 2026-05-15 · Reviewed by SupplementScore editors · No sponsorships

Hashimoto's thyroiditis is the dominant cause of hypothyroidism in iodine-sufficient countries. The supplement layer has one solid evidence-graded intervention (selenium for anti-TPO reduction), several deficiency-corrective layers (vitamin D, iron, B12 — frequently low in Hashimoto's cohorts), and a long list of well-marketed but poorly-evidenced "thyroid support" products that ride on the appearance of helping while doing little. Iodine excess can actively worsen the disease, which is the most important thing to know before walking into a supplement aisle.

This is a chronic autoimmune disease that needs medical management. Levothyroxine remains the standard of care when overt hypothyroidism develops. Symptoms attributed to "Hashimoto's" without TSH/FT4 confirmation may have other explanations (anaemia, B12 deficiency, depression, sleep apnoea, perimenopause). Endocrinology evaluation is appropriate for subclinical hypothyroidism, large goitres, and persistent symptoms despite normalised labs.

What actually has trial evidence

Tier 2 evidence · Multiple RCTs and meta-analyses

Selenium (selenomethionine)

200 mcg/day selenomethionine for 6 months minimum

The Toulis 2010 and Wichman 2016 meta-analyses converge: selenium at 200 mcg/day reduces anti-TPO antibody titres at 3 and 6 months in Hashimoto's, particularly in seleno-replete European cohorts. Clinical endpoints (TSH normalisation, levothyroxine dose reduction, quality of life) are softer but trend positive. Selenium is incorporated into glutathione peroxidases that detoxify the H2O2 generated during thyroid hormone synthesis — a mechanistically plausible repair pathway in an inflamed gland. Cap at 200 mcg/day; long-term dosing above 400 mcg/day risks selenosis.

Tier 2 evidence · Deficiency-corrective

Vitamin D3 (in confirmed deficiency)

2,000–4,000 IU/day to 25-OH-D 30–50 ng/mL

Vitamin D deficiency is more common in Hashimoto's cohorts than in matched controls. Several trials suggest repletion modestly reduces anti-TPO titres; results inconsistent for users already vitamin-D-replete. Test 25-OH-D first; supplement to target. Avoid pan-supplementation in already-replete users.

Tier 2 evidence · Often overlooked

Iron (ferrous bisglycinate, if ferritin low)

25–30 mg elemental every other day with vitamin C, on empty stomach

Iron deficiency is common in Hashimoto's, particularly in menstruating women, and worsens fatigue/cold intolerance attributable to thyroid disease. Iron is also required for the thyroid peroxidase enzyme. Stoffel 2017 shows alternate-day dosing improves absorption vs daily. Take ≥4 hours apart from levothyroxine (iron impairs absorption). Test ferritin and treat to >50 ng/mL. Beyond that, evidence for routine iron supplementation in iron-replete patients is absent.

Tier 2 evidence · Common comorbid deficiency

Vitamin B12 (methylcobalamin if deficient)

1,000 mcg/day methylcobalamin oral, or address atrophic gastritis if present

Autoimmune atrophic gastritis (anti-parietal-cell, anti-intrinsic-factor) co-occurs with Hashimoto's in a polyglandular autoimmune pattern. Pernicious anaemia and B12 deficiency are 3–5× more common in Hashimoto's than controls. Test serum B12 and methylmalonic acid; supplement on deficiency. Sublingual or IM B12 may be needed in pernicious anaemia.

Tier 3 evidence · Lower-confidence adjunct

Myo-inositol (with selenium)

600 mg myo-inositol + 83 mcg selenium b.i.d.

Nordio and colleagues' Italian trials suggest myo-inositol added to selenium produces additional TSH and anti-TPO reductions over selenium alone in subclinical hypothyroidism. The trials are small, single-centre, and somewhat industry-linked, but the side effects are minimal and the rationale (insulin/IGF-1 axis modulation in thyroid follicular cells) is mechanistically reasonable.

The lifestyle and behavioural base — usually higher yield than supplements

What to skip

What to track

TSH, FT4, and anti-TPO at baseline and at 6–12 month intervals. The supplement endpoint to track is anti-TPO titre at 6 months on selenium (a 30–50% drop is a meaningful response). Track symptoms with a structured scale — the ThyPRO patient-reported outcome covers Hashimoto's symptom domains. Don't chase TPO to zero — antibodies often persist long after immunomodulation; clinical hypothyroidism management drives the levothyroxine decisions.

Practical quick-start. Get baseline TSH, FT4, anti-TPO, 25-OH-D, ferritin, B12, and methylmalonic acid. Supplement deficiencies with targeted, dose-appropriate forms. Add selenomethionine 200 mcg/day for a 6-month trial — recheck anti-TPO. Treat overt hypothyroidism with levothyroxine under endocrinology guidance. Address modifiable lifestyle (sleep, exercise, dietary pattern, smoking). Avoid high-dose iodine, kelp, and "thyroid support" combination products that contain unpredictable iodine.

Sources

Read more: